Latest News
-
Tuesday - May 21, 2013
Novel ideas for mobility, construction and IT:
Bayer opens Innovation Hub for Asia Pacific
More than 200 experts to be employed in Shanghai » more
-
Monday - May 20, 2013
Not intended for U.S. and UK Media - American Thoracic Society International Conference, Philadelphia, USA:
Bayer Presents Positive Interim Results from Long-term Extension Study PATENT-2 with Riociguat
Riociguat showed good long-term safety profile(1) / Riociguat demonstrated significant and sustained improvements in six minute walking distance (6MWD) and WHO functional class (FC) in patients with pulmonary arterial hypertension (PAH)(1) » more
-
Friday - May 17, 2013
Not intended for U.S. and UK Media
Bayer Submits Investigational Drug Riociguat for Patients with Chronic Thromboembolic Pulmonary Hypertension for Regulatory Approval in Japan » more
-
Thursday - May 16, 2013
Strategic move to strengthen Consumer Care business:
Bayer to acquire Steigerwald Arzneimittelwerk GmbH
Transaction includes Iberogast® and Laif® brands » more
-
Thursday - May 16, 2013
Not intended for U.S. and UK Media - 49th Annual Meeting of the American Society of Clinical Oncology (ASCO):
Bayer to Present New Data Across Oncology Portfolio at ASCO 2013
First presentation of final analysis from pivotal Phase III DECISION trial of Nexavar (sorafenib) in patients with differentiated thyroid cancer presented as Plenary Abstract in Oral Abstract Session / Data presentations for three oncology products across five tumor types » more
-
Wednesday - May 15, 2013
Not intended for U.S. and UK Media
Bayer Receives U.S. FDA Approval for Cancer Treatment Xofigo® (radium 223 dichloride) Injection
New treatment for castration-resistant prostate cancer (CRPC) patients with bone metastases / Xofigo shown in a pivotal Phase III trial to significantly improve overall survival » more
-
Wednesday - May 15, 2013
Growing weed resistance drives demand for alternative technologies:
Bayer CropScience announces intention to construct a state-of-the-art facility for glufosinate-ammonium herbicide » more
-
Wednesday - May 15, 2013
Dr. Herbert Heitmann to be new Head of Communications and Government Relations at Bayer » more
-
Wednesday - May 15, 2013
Not intended for U.S. and UK Media
Bayer Initiates Phase III Trial of Regorafenib in Patients with Advanced Liver Cancer » more
-
Tuesday - May 14, 2013
Bayer Head of Communications will join soccer team
Michael Schade will become Managing Director of Bayer 04 Leverkusen » more
-
Friday - May 10, 2013
Bayer HealthCare Demonstrates Successful Integration of the Company’s Largest-Ever Animal Health Acquisition » more
-
Wednesday - May 8, 2013
Development know-how is made available to collaboration partners:
Bayer MaterialScience brings nano projects to a close » more
-
Wednesday - May 8, 2013
Not intended for U.S. and UK Media - The American Thoracic Society International Conference 2013:
Bayer to Present Data on Pulmonary Hypertension Research at the ATS International Conference 2013 in Philadelphia
Interim Analysis from Long-Term Extension Study PATENT-2 Phase III / Hemodynamic data and clinical correlation from CHEST-1 Phase III / New Data Sets from Pivotal PATENT-1 Phase III » more
-
Wednesday - May 8, 2013
Bayer HealthCare enables new online resource to fight vector-borne diseases
New canine vector-borne disease webinar will support veterinarians to diagnose and treat vector-borne diseases which can also be transmitted to humans » more
-
Tuesday - May 7, 2013
Not intended for UK Media
Bayer commences cash tender offer for all outstanding shares of Conceptus, Inc. » more
-
Tuesday - May 7, 2013
Not intended for U.S. and UK Media - Cardiovascular Disease Prevention:
Bayer HealthCare joins forces with Stroke Alliance for Europe to prevent Cardiovascular Disease
International opinion leaders raise awareness for societal burden resulting from cardiovascular disease » more
-
Tuesday - May 7, 2013
Sustainable Development Report 2012:
Bayer documents economic, social and ecological performance
Bayer CEO Dekkers: “Innovation and sustainability are the driving force behind our business success” / Integrated reporting from 2014 » more
-
Monday - May 6, 2013
Not intended for U.S. and UK Media
Bayer HealthCare Presents New Incubator Model for Biotech Startup Companies in Berlin
Second CoLaborator with dedicated lab space now at Bayer HealthCare Research & Development Center in Berlin / Shared lab space for promising life science startup companies to help them get their start » more
-
Friday - May 3, 2013
Not intended for UK Media
Bayer Provides Update on Phase II/III Trial of BAY 86-6150 » more
-
Friday - May 3, 2013
Board Member Dr. Rüdiger Scheitza to retire
Bayer CropScience announces organizational and personnel changes at the Excecutive Committee » more
Copyright @ Bayer AG